Literature DB >> 1813784

Aluminum: effects on bone and role in the pathogenesis of renal osteodystrophy.

W G Goodman1, M E Duarte.   

Abstract

Renal osteodystrophy is a complex disorder that can produce a variety of histologic changes in bone. Classically, excess parathyroid hormone (PTH) secretion in patients with chronic renal failure leads to the development of skeletal lesions characterized by increases in bone cell activity and by high rates of bone formation and turnover. In contrast, aluminium retention in the body in those undergoing long-term dialysis is often associated with diminished bone cell activity and bone formation. In some patients with renal osteodystrophy, both pathogenic factors may be operative. Thus the histologic features in an individual patient can represent the combined manifestations of both excess PTH secretion and bone aluminum toxicity; the relative roles of each of these two pathogenic processes must be carefully evaluated. In the current review, several pathophysiologic mechanisms of aluminum toxicity in bone are summarized.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1813784

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  5 in total

Review 1.  Renal osteodystrophy for nonnephrologists.

Authors:  William G Goodman
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 2.  Osteoporosis in children and adolescents: etiology and management.

Authors:  Giampiero Igli Baroncelli; Silvano Bertelloni; Federica Sodini; Giuseppe Saggese
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.

Authors:  Feng-Xiang Yan; M Chris Langub; Mark A Ihnen; Carlton Hornung; Erkki Juronen; Mary K Rayens; Wei-Min Cai; Peter J Wedlund; Paolo Fanti
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 4.  Role of bone biopsy in stages 3 to 4 chronic kidney disease.

Authors:  Anca Gal-Moscovici; Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

Review 5.  Drug-induced disorders of bone metabolism. Incidence, management and avoidance.

Authors:  G Jones; P N Sambrook
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.